State Street SPDR S&P Biotech ETF
196 hedge funds and large institutions have $3.25B invested in State Street SPDR S&P Biotech ETF in 2015 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 55 increasing their positions, 76 reducing their positions, and 33 closing their positions.
15% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 33
2% more funds holding
Funds holding: 193 → 196 (+3)
18% less capital invested
Capital invested by funds: $3.95B → $3.25B (-$702M)
28% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 76
45% less funds holding in top 10
Funds holding in top 10: 11 → 6 (-5)
61% less call options, than puts
Call options by funds: $525M | Put options by funds: $1.34B
295.26% less ownership
Funds ownership: 454.52% → 159.26% (-295%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$417M |
| 2 |
Goldman Sachs
New York
|
+$138M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$59.2M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$43.3M |
| 5 |
TI
Think Investments
San Francisco,
California
|
+$28.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$130M |
| 2 |
Citigroup
New York
|
-$73.1M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$31.4M |
| 4 |
JP Morgan Chase
New York
|
-$27.9M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$21.6M |
XBI Hedge Fund Activity: Q3 2015 in Review
196 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2015, worth a combined $3.25B — down 18% from $3.95B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new XBI positions and 33 closed out — a net gain of 5 holders — while 55 added to existing stakes and 76 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $417M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $130M.
- 196 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2015, up from 193 in Q2 2015.
- Funds reported $3.25B of State Street SPDR S&P Biotech ETF stock for Q3 2015, down 18% quarter-over-quarter.
- 38 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2015 and 33 closed out, a net change of +5 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2015 was Morgan Stanley, an estimated $417M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2015 was BNP Paribas Financial Markets, an estimated $130M sold.
Based on aggregated 13F filings for Q3 2015.